Literature DB >> 33410898

Stage I DLBCL: extranodal may mean extra radiation.

Izidore S Lossos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33410898      PMCID： PMC7808013          DOI： 10.1182/blood.2020008108

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  9 in total

1.  Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

Authors:  Michael B Møller; Niels T Pedersen; Bjarne E Christensen
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

2.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  Christophe Bonnet; Georges Fillet; Nicolas Mounier; Gérard Ganem; Thierry Jo Molina; Catherine Thiéblemont; Christophe Fermé; Bruno Quesnel; Claude Martin; Christian Gisselbrecht; Hervé Tilly; Félix Reyes
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

Authors:  Félix Reyes; Eric Lepage; Gérard Ganem; Thierry J Molina; Pauline Brice; Bertrand Coiffier; Pierre Morel; Christophe Ferme; Andre Bosly; Pierre Lederlin; Guy Laurent; Hervé Tilly
Journal:  N Engl J Med       Date:  2005-03-24       Impact factor: 91.245

4.  A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

Authors:  Peter J Hosein; Jocelyn C Maragulia; Matthew P Salzberg; Oliver W Press; Thomas M Habermann; Julie M Vose; Martin Bast; Ranjana H Advani; Robert Tibshirani; Andrew M Evens; Nahida Islam; John P Leonard; Peter Martin; Andrew D Zelenetz; Izidore S Lossos
Journal:  Br J Haematol       Date:  2014-01-27       Impact factor: 6.998

5.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

6.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

7.  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Authors:  Viola Poeschel; Gerhard Held; Marita Ziepert; Mathias Witzens-Harig; Harald Holte; Lorenz Thurner; Peter Borchmann; Andreas Viardot; Martin Soekler; Ulrich Keller; Christian Schmidt; Lorenz Truemper; Rolf Mahlberg; Reinhard Marks; Heinz-Gert Hoeffkes; Bernd Metzner; Judith Dierlamm; Norbert Frickhofen; Mathias Haenel; Andreas Neubauer; Michael Kneba; Francesco Merli; Alessandra Tucci; Peter de Nully Brown; Massimo Federico; Eva Lengfelder; Alice di Rocco; Ralf Trappe; Andreas Rosenwald; Christian Berdel; Martin Maisenhoelder; Ofer Shpilberg; Josif Amam; Konstantinos Christofyllakis; Frank Hartmann; Niels Murawski; Stephan Stilgenbauer; Maike Nickelsen; Gerald Wulf; Bertram Glass; Norbert Schmitz; Bettina Altmann; Markus Loeffler; Michael Pfreundschuh
Journal:  Lancet       Date:  2019-12-21       Impact factor: 79.321

8.  R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Authors:  Thierry Lamy; Gandhi Damaj; Pierre Soubeyran; Emmanuel Gyan; Guillaume Cartron; Krimo Bouabdallah; Rémy Gressin; Jérôme Cornillon; Anne Banos; Katell Le Du; Mohamed Benchalal; Marie-Pierre Moles; Steven Le Gouill; Joel Fleury; Pascal Godmer; Hervé Maisonneuve; Eric Deconinck; Roch Houot; Kamel Laribi; Jean Pierre Marolleau; Olivier Tournilhac; Bernard Branger; Anne Devillers; Jean Philippe Vuillez; Thierry Fest; Philippe Colombat; Valérie Costes; Vanessa Szablewski; Marie C Béné; Vincent Delwail
Journal:  Blood       Date:  2017-10-23       Impact factor: 25.476

9.  Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.

Authors:  Sabela Bobillo; Erel Joffe; Jessica A Lavery; David Sermer; Paola Ghione; Ariela Noy; Philip C Caron; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew J Matasar; Alison Moskowitz; Collette N Owens; M Lia Palomba; Connie L Batlevi; David Straus; Gottfried von Keudell; Andrew D Zelenetz; Joachim Yahalom; Ahmet Dogan; Venkatraman E Seshan; Anas Younes
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476
  9 in total
  1 in total

1.  Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma.

Authors:  Varsha Gupta; Vinit Singh; Ravneet Bajwa; Trishala Meghal; Shuvendu Sen; David Greenberg; Madhurima Anne; Michael J Levitt
Journal:  J Hematol       Date:  2022-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.